71 completed, 36 recruiting, 26 terminated, 24 unknown. 190 Phase 1, 73 Phase 2.
Follow Acute Lymphoblastic Leukemia: new trials by email Literature Review of Acute Lymphoblastic Leukemia trials Research Report on Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers huCART19-IL18-CD428z cells - Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Not yet recruiting | University of Pennsylvania | 6 | 2027-01-01 | 2026-11-02 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-12-01 | 2026-10-26 |
| Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) TSLPR-CART, Cyclophosphamide, Fludarabine - B-All, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | National Cancer Institute (NCI) | 57 | 2026-11-08 | 2026-11-03 |
| HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies Capivasertib, Venetoclax, Dexamethasone - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Phase 1 / Phase 2 | Not yet recruiting | Princess Maxima Center for Pediatric Oncology | 42 | 2026-10-01 | 2025-09-16 |
| A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Withdrawn | Children's Oncology Group | 2026-09-10 | 2026-05-05 | |
| A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation - Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 46 | 2026-09-09 | 2026-10-23 |
| Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) Asciminib Adult formulation, Asciminib Pediatric formulation, Dexamethasone - Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 50 | 2026-07-05 | 2026-10-15 |
| Phase I Study of FXS0683 in the Treatment of Blood Tumors FXS0683 - B-Cell Lymphoma, Acute Myeloid Leukemia | Phase 1 | Recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 228 | 2026-06-02 | 2026-10-14 |
| A Study of Revumenib and Mezigdomide in People With Leukemia Revumenib, Mezigdomide - Leukemia, Acute Leukemia | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 52 | 2026-01-16 | 2026-10-20 |
| A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias JNJ-75276617, Fludarabine, Cytarabine - Acute Leukemias, Acute Myeloid Leukemia | Phase 1 | Withdrawn | Janssen Research & Development, LLC | 2025-12-26 | 2025-06-22 | |
| Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies LV009 Injection - Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2025-12-03 | 2025-12-16 |
| A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia 14C-bleximenib, bleximenib - Acute Lymphoblastic Leukemia, Acute Leukemias | Phase 1 | Completed | Janssen Research & Development, LLC | 6 | 2025-11-18 | 2026-09-25 |
| HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies Dasatinib, Venetoclax, Dexamethasone - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Phase 1 / Phase 2 | Recruiting | Princess Maxima Center for Pediatric Oncology | 26 | 2025-10-01 | 2025-09-16 |
| CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study CD19 CAR-T cells injection - Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Zhujiang Hospital | 30 | 2025-07-19 | 2025-07-18 |
| A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL ARM011, Fludarabine, Cyclophosphamide - Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | TriArm Therapeutics (Taiwan) Limited | 12 | 2025-07-15 | 2025-07-23 |
| 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome Actinium Ac 225-DOTA-Daratumumab, Biospecimen Collection, Bone Marrow Aspiration - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2025-07-01 | 2026-10-30 |
| CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia Fludarabine, Cyclophosphamide, Mesna - Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 30 | 2025-04-28 | 2026-05-19 |
| A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies RS001 injection - B-cell Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia | Phase 1 | Not yet recruiting | Guangdong Ruishun Biotech Co., Ltd | 13 | 2025-04-01 | 2025-03-25 |
| Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Leukemia, Acute Leukemia of Ambiguous Lineage | Phase 1 | Recruiting | City of Hope Medical Center | 27 | 2024-12-31 | 2026-10-19 |
| CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children. CAR-T Therapy - Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Guangzhou Women and Children's Medical Center | 10 | 2024-10-01 | 2024-12-31 |
Showing 20 of 190. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (190) · Leukemia, Myeloid, Acute (86) · Myelodysplastic Syndromes (48) · Lymphoma, Non-Hodgkin (41) · Leukemia (37) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (32) · Leukemia, Lymphocytic, Chronic, B-Cell (25) · Hodgkin Disease (17) · Burkitt Lymphoma (14) · Leukemia, Biphenotypic, Acute (14) · Multiple Myeloma (14) · Lymphoma (13) · Lymphoma, B-Cell (13) · Recurrence (12) · Lymphoma, Large B-Cell, Diffuse (11)
Hemic and Lymphatic Diseases (190) · Immune System Diseases (189) · Leukemia, Lymphoid (189) · Lymphatic Diseases (189) · Neoplasms by Histologic Type (189) · Hematologic Diseases (188) · Immunoproliferative Disorders (188) · Lymphoproliferative Disorders (186) · Neoplasms (181) · Leukemia (153) · Leukemia, Myeloid (91) · Pathologic Processes (71) · Pathological Conditions, Signs and Symptoms (71) · Disease Attributes (65) · Lymphoma (64)
Cyclophosphamide (35) · fludarabine (21) · Dexamethasone (18) · Cytarabine (16) · Vincristine (14) · fludarabine phosphate (13) · Methotrexate (12) · pegaspargase (11) · Clofarabine (8) · Doxorubicin (8) · Calcium Dobesilate (7) · Melphalan (7) · AP 1903 reagent (6) · Immunotherapy, Adoptive (6) · Mercaptopurine (6)
City of Hope Medical Center (6) · M.D. Anderson Cancer Center (6) · National Cancer Institute (NCI) (6) · Novartis Pharmaceuticals (6) · St. Jude Children's Research Hospital (6) · Baylor College of Medicine (4) · Bellicum Pharmaceuticals (4) · Memorial Sloan Kettering Cancer Center (4) · University of Pennsylvania (4) · Wuhan Sian Medical Technology Co., Ltd (4) · Fred Hutchinson Cancer Center (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · Therapeutic Advances in Childhood Leukemia Consortium (3) · ADC Therapeutics S.A. (2) · Children's Oncology Group (2)
United States (116) · China (25) · Italy (15) · Canada (12) · France (12) · Germany (12) · Netherlands (10) · United Kingdom (10) · Spain (9) · Australia (8) · Israel (5) · Austria (4) · Japan (4) · Belgium (3) · Denmark (3)
Heng Mei, M.D., Ph.D (3) · Andrej Lissat, MD PhD (2) · Benjamin Tomlinson, MD (2) · Jae Park, MD (2) · Jeffrey Y Wong (2) · Lewis Silverman, MD (2) · Minocher M Battiwalla, M.D. (2) · Nirali N Shah, M.D. (2) · Sima Jeha, MD (2) · Wendy Stock, MD (2) · YU HU, M.D., Ph.D (2)
PMID 40195173, PMID 41671463, PMID 33741715, PMID 34267079, PMID 34687939, PMID 35799791, PMID 37486616, PMID 18824593, PMID 19029442, PMID 19965642, PMID 20582937, PMID 21849486, PMID 21967976, PMID 22047558, PMID 22653976, PMID 23233571, PMID 24355079, PMID 24753538, PMID 24869942, PMID 25082342, PMID 25612623, PMID 25733005, PMID 25933833, PMID 25977584, PMID 26072403, PMID 26341814, PMID 26639404, PMID 26687796, PMID 27063977, PMID 27063978, PMID 27198129, PMID 27998223, PMID 28039295, PMID 28588018, PMID 28983018, PMID 29385376, PMID 29481659, PMID 29724899, PMID 29908231, PMID 30335787, PMID 31355467, PMID 31401903, PMID 31477906, PMID 31770437, PMID 31969338, PMID 32012214, PMID 32084260, PMID 32286905, PMID 32521310, PMID 32582591
P30CA033572 (5), 2025 (2), P01CA078902 (2), U10CA180886 (2), 2008 (1), 2015 (1), 2016 (1), 2018 (1), 2023 (1), N01CM00071 (1), N01CM62201 (1), N01CM62209 (1), P30CA006973 (1), P30CA015704 (1), P30CA069533 (1)